Profile cover photo
Profile photo
DelMar Pharmaceuticals, Inc.
15 followers -
DelMar (NASDAQ:DMPI) develops cancer therapies in new indications where patients have failed/unlikely to respond to modern therapy. Clinical trial in GBM
DelMar (NASDAQ:DMPI) develops cancer therapies in new indications where patients have failed/unlikely to respond to modern therapy. Clinical trial in GBM

15 followers
About
DelMar Pharmaceuticals, Inc.'s posts

Post has attachment
Approximately 17,000 people are diagnosed with a primary brain tumor each year in the U.S. Click for more brain tumor facts from MD Anderson Cancer Center:

Post has attachment
Dr. James Perry discussed DelMar's VAL-083 as a potential treatment for glioblastoma multiforme at our recent KOL event. Listen to a webcast replay here:

Post has attachment
The risk of developing ovarian cancer gets higher with age with half of all ovarian cancers found in women 63 years of age or older.

Post has attachment
Gord Downie's neuro oncologist, Dr. James Perry, highlights how his courage to continue performing following his glioblastoma diagnosis provides hope, awareness and needed funds to brain cancer patients.

Post has attachment
Dallas News reporter Jeffrey Weiss details his diagnosis with glioblastoma, how it has affected his life and reports on his research of the disease and journey to treatment.

Post has attachment
Dr. James Perry, neuro-oncologist and head of Sunnybrook’s Neurology Program, discusses his work in the diagnosis and treatment of brain tumours of the nervous system. “These patients and their families need a voice, an advocate, a researcher,” Dr. Perry said. “We want to provide the best care possible and also invent the future of care.”

Post has attachment
DelMar is studying VAL-083 as a potential treatment for GBM patients that have failed or whose tumors express biological features, such as a high expression of MGMT.

Post has attachment
The American Cancer Society estimates there will be about 222,500 new cases of lung cancer in the U.S. in 2017.

Post has attachment
The median survival for glioblastoma patients treated with the current standard of care is about 14.6 months.

Post has attachment
About 17,000 people are diagnosed with primary brain cancer every year in the United States. Find more brain tumor facts here from the MD Anderson Cancer Center.
Wait while more posts are being loaded